Rezolute Faces Major Stock Plunge and Fraud Investigations Following Phase 3 Trial Failures
RZLT's stock dropped nearly 90% after Phase 3 trial failure. The trial did not meet the primary endpoint for ersodetug. Securities law investigations may ensue following this announcement. Potential investor actions could arise due to the trial's outcome. Phase 3 failure raises significant concerns for RZLT's future.
View signal analysis